|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sugden MC and Holness MJ: Mechanisms
underlying regulation of the expression and activities of the
mammalian pyruvate dehydrogenase kinases. Arch Physiol Biochem.
112:139–149. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kinnaird A, Dromparis P, Saleme B, Gurtu
V, Watson K, Paulin R, Zervopoulos S, Stenson T, Sutendra G, Pink
DB, et al: Metabolic modulation of clear-cell renal cell carcinoma
with dichloroacetate, an inhibitor of pyruvate dehydrogenase
kinase. Eur Urol. 69:734–744. 2016. View Article : Google Scholar
|
|
6
|
Bonnet S, Archer SL, Allalunis-Turner J,
Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta
L, Bonnet S, et al: A mitochondria-K+ channel axis is
suppressed in cancer and its normalization promotes apoptosis and
inhibits cancer growth. Cancer Cell. 11:37–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saunier E, Benelli C and Bortoli S: The
pyruvate dehydrogenase complex in cancer: An old metabolic
gatekeeper regulated by new pathways and pharmacological agents.
Int J Cancer. 138:809–817. 2016. View Article : Google Scholar
|
|
8
|
Leclerc D, Pham DN, Lévesque N, Truongcao
M, Foulkes WD, Sapienza C and Rozen R: Oncogenic role of PDK4 in
human colon cancer cells. Br J Cancer. 116:930–936. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Trinidad AG, Whalley N, Rowlinson R,
Delpuech O, Dudley P, Rooney C and Critchlow SE: Pyruvate
dehydrogenase kinase 4 exhibits a novel role in the activation of
mutant KRAS, regulating cell growth in lung and colorectal tumour
cells. Oncogene. 36:6164–6176. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stacpoole PW: Therapeutic targeting of the
pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase
(PDC/PDK) axis in cancer. J Natl Cancer Inst. 109:2017 View Article : Google Scholar
|
|
11
|
Sutendra G and Michelakis ED: Pyruvate
dehydrogenase kinase as a novel therapeutic target in oncology.
Front Oncol. 3:382013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kankotia S and Stacpoole PW:
Dichloroacetate and cancer: New home for an orphan drug? Biochim
Biophys Acta. 1846:617–629. 2014.PubMed/NCBI
|
|
13
|
Yamane K, Indalao IL, Chida J, Yamamoto Y,
Hanawa M and Kido H: Diisopropylamine dichloroacetate, a novel
pyruvate dehydrogenase kinase 4 inhibitor, as a potential
therapeutic agent for metabolic disorders and multiorgan failure in
severe influenza. PLoS One. 9:e980322014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chu QS, Sangha R, Spratlin J, Vos LJ,
Mackey JR, McEwan AJ, Venner P and Michelakis ED: A phase I
open-labeled, single-arm, dose-escalation, study of dichloroacetate
(DCA) in patients with advanced solid tumors. Invest New Drugs.
33:603–610. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tambe Y, Terado T, Kim CJ, Mukaisho K,
Yoshida S, Sugihara H, Tanaka H, Chida J, Kido H, Yamaji K, et al:
Antitumor activity of potent pyruvate dehydrogenase kinase 4
inhibitors from plants in pancreatic cancer. Mol Carcinog.
58:1726–1737. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fares J, Fares MY, Khachfe HH, Salhab HA
and Fares Y: Molecular principles of metastasis: A hallmark of
cancer revisited. Signal Transduct Target Ther. 5:282020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dillekås H, Rogers MS and Straume O: Are
90% of deaths from cancer caused by metastases? Cancer Med.
8:5574–5576. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kamarajugadda S, Stemboroski L, Cai Q,
Simpson NE, Nayak S, Tan M and Lu J: Glucose oxidation modulates
anoikis and tumor metastasis. Mol Cell Biol. 32:1893–1907. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han T, Kang D, Ji D, Wang X, Zhan W, Fu M,
Xin HB and Wang JB: How does cancer cell metabolism affect tumor
migration and invasion? Cell Adh Migr. 7:395–403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gatenby RA and Gawlinski ET: The
glycolytic phenotype in carcinogenesis and tumor invasion: Insights
through mathematical models. Cancer Res. 63:3847–3854.
2003.PubMed/NCBI
|
|
21
|
Williams AC, Collard TJ and Paraskeva C:
An acidic environment leads to p53 dependent induction of apoptosis
in human adenoma and carcinoma cell lines: Implications for clonal
selection during colorectal carcinogenesis. Oncogene. 18:3199–3204.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lardner A: The effects of extracellular pH
on immune function. J Leukoc Biol. 69:522–530. 2001.PubMed/NCBI
|
|
23
|
GLOBCAN 2018 Cancer fact sheet: Bladder.
http://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf.
Accessed December 22, 2020.
|
|
24
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wahafu W, Liu S, Xu W, Wang M, He Q, Song
L, Wang M, Yang F, Hua L, Niu Y and Xing N: The long-term efficacy
of one-shot neoadjuvant intra-arterial chemotherapy combined with
radical cystectomy versus radical cystectomy alone for bladder
cancer: A propensity-score matching study. BMC Urol. 19:1172019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goto T and Miyamoto H: Why has the
prognosis for muscle-invasive bladder cancer not significantly
improved after decades of therapeutic advancements? Expert Rev
Anticancer Ther. 20:229–231. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Woolbright BL, Choudhary D, Mikhalyuk A,
Trammel C, Shanmugam S, Abbott E, Pilbeam CC and Taylor JA III: The
role of pyruvate dehydrogenase Kinase-4 (PDK4) in bladder cancer
and chemoresistance. Mol Cancer Ther. 17:2004–2012. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim CJ, Terado T, Tambe Y, Mukaisho K,
Sugihara H, Kawauchi A and Inoue H: Anti-oncogenic activities of
cyclin D1b siRNA on human bladder cancer cells via induction of
apoptosis and suppression of cancer cell stemness and invasiveness.
Int J Oncol. 52:231–240. 2018.
|
|
29
|
Kim CJ, Nishi K, Isono T, Okuyama Y, Tambe
Y, Okada Y and Inoue H: Cyclin D1b variant promotes cell
invasiveness independent of binding to CDK4 in human bladder cancer
cells. Mol Carcinog. 48:953–964. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Q, Miao S, Han X, Li C, Zhang M, Cui
K, Xiong T, Chen Z, Wang C and Xu H: MicroRNA-3619-5p suppresses
bladder carcinoma progression by directly targeting β-catenin and
CDK2 and activating p21. Cell Death Dis. 9:9602018. View Article : Google Scholar
|
|
31
|
Tambe Y, Hasebe M, Kim CJ, Yamamoto A and
Inoue H: The drs tumor suppressor regulates glucose metabolism via
lactate dehydrogenase-B. Mol Carcinog. 55:52–63. 2016. View Article : Google Scholar
|
|
32
|
Zhang W, Zhang SL, Hu X and Tam KY:
Targeting tumor metabolism for cancer treatment: Is pyruvate
dehydrogenase kinases (PDKs) a viable anticancer target? Int J Biol
Sci. 11:1390–1400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weiswald LB, Bellet D and Dangles-Marie V:
Spherical cancer models in tumor biology. Neoplasia. 17:1–15. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fang D, Hawke D, Zheng Y, Xia Y,
Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T and Lu Z:
Phosphorylation of beta-catenin by Akt promotes beta-catenin
transcriptional activity. J Biol Chem. 282:11221–11229. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mulholland DJ, Dedhar S, Coetzee GA and
Nelson CC: Interaction of nuclear receptors with the
Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr
Rev. 26:898–915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Daugherty RL and Gottardi CJ:
Phospho-regulation of Beta-catenin adhesion and signaling
functions. Physiology (Bethesda). 22:303–309. 2007.
|
|
37
|
Han J, Xie C, Pei T, Wang J, Lan Y, Huang
K, Cui Y, Wang F, Zhang J, Pan S, et al: Deregulated
AJAP1/β-catenin/ZEB1 signaling promotes hepatocellular carcinoma
carcinogenesis and metastasis. Cell Death Dis. 8:e27362017.
View Article : Google Scholar
|
|
38
|
Higuchi T, Yokobori T, Naito T, Kakinuma
C, Hagiwara S, Nishiyama M and Asao T: Investigation into
metastatic processes and the therapeutic effects of gemcitabine on
human pancreatic cancer using an orthotopic SUIT-2 pancreatic
cancer mouse model. Oncol Lett. 15:3091–3099. 2018.PubMed/NCBI
|
|
39
|
Lu Z, Ghosh S, Wang Z and Hunter T:
Downregulation of caveolin-1 function by EGF leads to the loss of
E-cadherin, increased transcriptional activity of beta-catenin, and
enhanced tumor cell invasion. Cancer Cell. 4:499–515. 2003.
View Article : Google Scholar
|
|
40
|
Jing Y, Cui D, Guo W, Jiang J, Jiang B, Lu
Y, Zhao W, Wang X, Jiang Q, Han B and Xia S: Activated androgen
receptor promotes bladder cancer metastasis via Slug mediated
epithelial-mesenchymal transition. Cancer Lett. 348:135–145. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gunthert U, Hofmann M, Rudy W, Reber S,
Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P:
A new variant of glycoprotein CD44 confers metastatic potential to
rat carcinoma cells. Cell. 65:12–24. 1991. View Article : Google Scholar
|
|
42
|
Nagano O and Saya H: Mechanism and
biological significance of CD44 cleavage. Cancer Sci. 95:930–935.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ponta H, Sherman L and Herrlich PA: CD44:
From adhesion molecules to signalling receptors. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
van Grevenstein WM, Hofland LJ, Jeekel J
and van Eijck CH: The expression of adhesion molecules and the
influence of inflammatory cytokines on the adhesion of human
pancreatic carcinoma cells to mesothelial monolayers. Pancreas.
32:396–402. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Abugomaa A, Elbadawy M, Yamawaki H, Usui T
and Sakaki K: Emerging roles of cancer stem cells in bladder cancer
progression, tumorigenesis, and resistance to chemotherapy: A
potential therapeutic target for bladder cancer. Cells. 9:2352020.
View Article : Google Scholar :
|
|
46
|
Brunner A, Prelog M, Verdorfer I, Tzankov
A, Mikuz G and Ensinger C: EpCAM is predominantly expressed in high
grade and advanced stage urothelial carcinoma of the bladder. J
Clin Pathol. 61:307–310. 2008. View Article : Google Scholar
|
|
47
|
Xia P and Xu X: PI3K/Akt/mTOR signaling
pathway in cancer stem cells: From basic research to clinical
application. Am J Cancer. 5:1602–1609. 2015.
|
|
48
|
Matsubara S, Ding Q, Miyazaki Y, Kuwahara
T, Tsukasa K and Takao S: mTOR plays critical roles in pancreatic
cancer stem cells through specific and stemness-related functions.
Sci Rep. 3:32302013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Deshmukh A, Deshpande K, Arfuso F,
Newsholme P and Dharmarajan A: Cancer stem cell metabolism: A
potential target for cancer therapy. Mol Cancer. 15:692016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cao ZQ, Wang Z and Leng P: Aberrant
N-cadherin expression in cancer. Biomed Phamacother.
118:1093202019. View Article : Google Scholar
|
|
51
|
Magaway C, Kim E and Jacinto E: Targeting
mTOR and metabolism in cancer: Lessons and innovations. Cells.
8:15842019. View Article : Google Scholar
|
|
52
|
Valvezan AJ and Manning BD: Molecular
logic of mTORC1 signalling as a metabolic rheostat. Nat Metab.
1:321–333. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zou Z, Tao T, Li H and Zhu X: mTOR
signaling pathway and mTOR inhibitors in cancer: Progress and
challenges. Cell Biosci. 10:312020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Prossomariti A, Piazzi G, Alquati C and
Ricciardiello L: Are Wnt/β-catenin and PI3K/AKT/MTORC1 distinct
pathways in colorectal cancer. Cell Mol Gastroenterol Hepatol.
10:491–506. 2020. View Article : Google Scholar :
|
|
55
|
Liu Y, Lin F, Chen Y, Wang R, Liu J, Jin J
and An R: Cryptotanshinone inhibits bladder cancer cell
proliferation and promotes apoptosis via the PTEN/PI3K/AKT pathway.
J Cancer. 11:488–499. 2020. View Article : Google Scholar :
|
